Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

May 20, 2027

Study Completion Date

May 20, 2027

Conditions
Recurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Venetoclax

Given PO

Trial Locations (12)

20892

SUSPENDED

NCI - Center for Cancer Research, Bethesda

21201

SUSPENDED

University of Maryland/Greenebaum Cancer Center, Baltimore

33021

RECRUITING

UM Sylvester Comprehensive Cancer Center at Hollywood, Hollywood

33065

RECRUITING

UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs

33136

RECRUITING

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33146

RECRUITING

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables

33176

RECRUITING

UM Sylvester Comprehensive Cancer Center at Kendall, Miami

33180

RECRUITING

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura

33442

RECRUITING

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

43210

SUSPENDED

Ohio State University Comprehensive Cancer Center, Columbus

45069

SUSPENDED

University of Cincinnati Cancer Center-West Chester, West Chester

45219

SUSPENDED

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH